Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neoplasms 23Carcinoma, Non-Small-Cell Lung 15Prostatic Neoplasms 14Stomach Neoplasms 12Colorectal Neoplasms 12Breast Neoplasms 12Pancreatic Neoplasms 10Leukemia, Myeloid, Acute 10Neoplasm Metastasis 9Lung Neoplasms 9Hematologic Neoplasms 9Head and Neck Neoplasms 9Carcinoma, Hepatocellular 9Squamous Cell Carcinoma of Head and Neck 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Ovarian Neoplasms 8Endometrial Neoplasms 8Myasthenia Gravis 7Melanoma 7Uterine Cervical Neoplasms 6Recurrence 6Rectal Neoplasms 6Neoplasms by Site 6Neoplasms by Histologic Type 6Lymphoma 6Leukemia 6Urinary Bladder Neoplasms 5Neoplasms, Plasma Cell 5Infections 5Colonic Neoplasms 5

Interventions

Paclitaxel 1Epirubicin 1Docetaxel 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Recruiting × HER2-negative Breast Cancer × Clear all
NCT04576143 2021-08-12

Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2/3 Recruiting
260 enrolled
Breast

HER2-negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡